Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity

12

May

2022

16:00

BST

17:00

CEST

Webinar

  • Views:

    Views Icon 7054
  • Likes:

    Heart Icon 13

Overview

Following a pan-European crowdsourcing survey, which assessed current practices, attitudes and knowledge on CV risk, we are delighted to have our esteemed faculty present the findings and put them into context of real-world practice.  

The survey, which compared results from European cardiologists and primary care providers, highlighted several interesting trends in prescribing practices and knowledge gaps in assessing patient risk. During this live webinar, our crowdsourcing results will serve as a basis to discuss several other large practice-based studies and to recap on current guideline-directed practice.

This symposium is supported by an unrestricted educational grant from Novartis.

Performed By:

Maciej Banach

Maciej Banach

Yassir Javaid

Yassir Javaid

Kausik (Kosh) Ray

Kausik (Kosh) Ray

Moderated By:

Lale Tokgözoğlu

Lale Tokgözoğlu

Agenda

Session 1: Current knowledge and practice gaps in hypercholesterolaemia management

Unmet needs in hypercholesterolaemia management

• What do we know already?
• Healthcare provider barriers
• Patient-physician barriers

Session 2: Further insight into physician and patient behaviour

• Further insight from a pan European crowdsourcing activity

Session 3: Addressing knowledge gaps in hypercholesterolaemia management

Current European guideline targets by risk category

• Current European guideline targets by risk category
• Defining risk categories
• Best practice for assessing risk
• LDL-targets (lower is better)
• Overview of LDL-C lowering drugs and their individual/combined LDL-C lowering capacity
• Patient education: how often and what we should be communicating

Session 4: Panel discussion

• How far is real-world practice from ideal standards?
• How can practices improve and how can we mitigate some of the barriers?
• What will the future hold in terms of new treatments and access to PCSK9is?

Key Learning Objectives

  • Discuss the current practice gaps in hypercholesterolaemia management
  • Review results of large retrospective trials which show varied use of lipid-lowering therapy and LDL-C target achievement
  • Stratify patients by CV risk category
  • Recall best practice for assessing CV risk, defining LDL-C target and offering patient education
  • Select appropriate cholesterol-lowering therapies according to risk category and LDL-C target
  • Discuss how current practices in the real-world deviate from guideline directed practice
  • Alter practices to mitigate barriers to optimal practice

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • CV Prevention Specialists
  • GPs and other primary care HCPs
  • Pharmacists

Faculty Biographies

Maciej Banach

Maciej Banach

Professor Maciej Banach is President of the Polish Mother's Memorial Hospital - Research Institute (PMMHRI), Head of the Cardiovascular Research Centre at University of Zielona Gora and Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI in Poland.

View full profile
Yassir Javaid

Yassir Javaid

Dr Javaid qualified from Cambridge University and completed his GP VTS training in Northampton. He has an interest in cardiology and echocardiography and was a clinical lead in the Northamptonshire Community Cardiology service, which had a focus on patients with heart failure and valve disease.

Dr Javaid was named Pulse “GP of the Year” in 2015 for his work in reducing stroke emergency admissions in the East Midlands. He is also a council member of the British Heart Valve Society, accredited member of the British Society of Echocardiography and on the editorial board for the British Journal of Cardiology.

View full profile
Kausik (Kosh) Ray

Kausik (Kosh) Ray

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.

Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 80, an i10 of 199 and over 80,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 69 countries and 61,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

View full profile
Lale Tokgözoğlu

Lale Tokgözoğlu

S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.

Professor Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee.  She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She has won the “Prof. Dr. Seref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994.

View full profile